


Assem Barakat*, M. Ali, Abdullah Mohammed Al-Majid, Mohammad Shahidul Islam and Hazem A. Ghabbour

Crystal structure of 5-((4-bromophenyl)(2-hydroxy-6-oxocyclohex-1-en-1-yl)methyl)-6-hydroxy-1,3-dimethylpyrimidine-2,4(1*H*,3*H*)-dione, C₁₉H₁₉BrN₂O₅



$V = 1829.71(14) \text{ \AA}^3$, $Z = 4$, $R_{\text{gt}}(F) = 0.0360$, $wR_{\text{ref}}(F^2) = 0.0772$, $T = 100 \text{ K}$.

CCDC no.: 1443066

The measurement method and a list of the atoms including atomic coordinates and displacement parameters summarized in Tables 1–3.

Table 1: Data collection and handling.

Crystal:	Block, Colourless, size $0.090 \times 0.124 \times 0.417 \text{ mm}$
Wavelength:	Mo K_{α} radiation ($0.71073 \text{ \AA}$)
μ :	22.81 cm^{-1}
Diffractometer, scan mode:	Bruker APEX-II, φ and ω scans
$2\theta_{\text{max}}$:	49.99°
$N(hkl)_{\text{measured}}$, $N(hkl)_{\text{unique}}$:	16043, 3222
$N(\text{param})_{\text{refined}}$:	254
Programs:	SAINT [12], SHELX [13]

DOI 10.1515/ncrs-2015-0288

Received December 18, 2015; accepted March 22, 2016; available online May 16, 2016

Abstract

C₁₉H₁₉BrN₂O₅, monoclinic, $P2_1/c$ (no. 14), $a = 10.2634(5) \text{ \AA}$, $b = 10.7951(4) \text{ \AA}$, $c = 17.0558(8) \text{ \AA}$, $\beta = 104.474(2)^\circ$,

***Corresponding author: Assem Barakat**, Department of Chemistry, College of Science, King Saud University, P. O. Box 2455, Riyadh 11451, Saudi Arabia; and Department of Chemistry, Faculty of Science, Alexandria University, P. O. Box 426, Ibrahimia, Alexandria 21321, Egypt, e-mail: mabrakat@ksu.edu.sa

M. Ali, Abdullah Mohammed Al-Majid and Mohammad Shahidul Islam: Department of Chemistry, College of Science, King Saud University, P. O. Box 2455, Riyadh 11451, Saudi Arabia

Hazem A. Ghabbour: Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P. O. Box. 2457, Riyadh 11451, Kingdom of Saudi Arabia; and Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt

Source of material

The synthesis of 5-((4-bromophenyl)(2-hydroxy-6-oxocyclohex-1-en-1-yl)methyl)-6-hydroxy-1,3-dimethylpyrimidine-2,4(1*H*,3*H*)-dione prepared according to reported method by Barakat et al. [1]. The precursors used in this study are commercially available. A mixture of 4-bromobenzaldehyde (1.5 mmol), cyclohexane-1,3-dione (1.5 mmol), 1,3-dimethylpyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione (1.5 mmol), and Et₂NH (1.5 mmol, 155 μL) in H₂O (3 mL, degassed). The reaction mixture was further stirred for 24 h at rt (Monitored by TLC). The desired compound was precipitated and filtered off, then recrystallized from a mixture of CH₂Cl₂/EtOH/Et₂O over 2 days and get single cube whitless crystal and to obtain the pure product.

Yield: 90%; m.p. 140°C ; IR (KBr, cm^{-1}) $\nu_{\text{max}} = 3055$, 2952, 2661, 1692, 1600, 1483, 1459, 1397, 1242; [Anal. Calcd. for C₁₉H₁₉BrN₂O₅ (%): C, 52.43; H, 4.40; Br, 18.36; N, 6.44;

Table 2: Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å²).

Atom	Site	<i>x</i>	<i>y</i>	<i>z</i>	<i>U</i> _{iso}
H(2A)	4e	1.0107	0.5352	0.8708	0.034
H(2B)	4e	0.9145	0.4213	0.8778	0.034
H(2C)	4e	0.9359	0.5313	0.9427	0.034
H(4A)	4e	0.8282	0.8167	0.6687	0.030
H(4B)	4e	0.6688	0.8300	0.6344	0.030
H(4C)	4e	0.7463	0.7154	0.6073	0.030
H(7A)	4e	0.4527	0.5004	0.8402	0.014
H(10A)	4e	0.3426	0.7298	1.0251	0.023
H(10B)	4e	0.1948	0.7055	0.9689	0.023
H(11A)	4e	0.3751	0.8987	0.9495	0.024
H(11B)	4e	0.2261	0.9157	0.9616	0.024
H(12A)	4e	0.1315	0.8324	0.8318	0.023
H(12B)	4e	0.2266	0.9465	0.8229	0.023
H(15A)	4e	0.1631	0.5697	0.7466	0.017
H(16A)	4e	0.0240	0.4696	0.6360	0.019
H(18A)	4e	0.3514	0.3453	0.5679	0.018
H(19A)	4e	0.4898	0.4484	0.6777	0.017
H(104)	4e	0.363(4)	0.520(4)	1.000(3)	0.06(1)
H(103)	4e	0.427(4)	0.750(4)	0.695(2)	0.05(1)

Found(%): C, 52.44; H, 4.42; Br, 18.36; N, 6.47; LC/MS (ESI, *m/z*): 435.27[M⁺].

Experimental details

The X-ray data for the synthesized compound were carried out by Bruker SAINT [12]. The chemical structure were solved by SHELX program (AFIX 13, 23, 43 or 137 option) [13].

Discussion

Barbituric acid is the key pharmacophore of several medicinal targets. For example bucolome, veronal, phenobarbital, seconal, and sodium pentothal representatives have clinical use as anti-inflammatory and hypnotic drugs which are derived from barbituric acid scaffold [2–4]. On the other hand, this scaffold possessing antitumor, anti-hypertensive, sedative, anticonvulsant, anti-oxidant, and anti-diabetic potentials [5–11]. We have described in this text the synthesis of a new pyrimidines derivatives *via* one pot Aldol-Michael reactions in aqueous diethylamine medium. The desired compound was characterized by spectroscopic techniques and by X-ray single crystal analysis.

The structure of the title molecule is shown in the figure. In the target compound molecules were stabilized by the two intermolecular hydrogen bonds and one intramolecular

Table 3: Fractional coordinates and atomic displacement parameters (Å²).

Atom	Site	<i>x</i>	<i>y</i>	<i>z</i>	<i>U</i> ₁₁	<i>U</i> ₂₂	<i>U</i> ₃₃	<i>U</i> ₁₂	<i>U</i> ₁₃	<i>U</i> ₂₃
Br(1)	4e	0.06106(3)	0.31594(3)	0.50239(2)	0.0184(2)	0.0311(2)	0.0184(2)	−0.0069(2)	0.0032(1)	−0.0062(2)
O(1)	4e	0.6812(2)	0.4943(2)	0.9091(1)	0.020(1)	0.023(1)	0.012(1)	0.006(1)	0.0049(9)	0.005(1)
O(2)	4e	0.9476(2)	0.6634(2)	0.7615(1)	0.013(1)	0.027(1)	0.032(1)	0.001(1)	0.012(1)	0.001(1)
O(3)	4e	0.5000(2)	0.7351(2)	0.6747(1)	0.015(1)	0.017(1)	0.015(1)	0.0035(9)	0.005(1)	0.004(1)
O(4)	4e	0.3734(2)	0.5296(2)	0.9503(1)	0.025(1)	0.020(1)	0.014(1)	0.008(1)	0.008(1)	0.005(1)
O(5)	4e	0.3120(2)	0.8040(2)	0.7331(1)	0.016(1)	0.016(1)	0.019(1)	0.0027(9)	0.0078(9)	0.006(1)
N(1)	4e	0.8129(2)	0.5772(2)	0.8344(2)	0.010(1)	0.016(1)	0.014(1)	0.003(1)	0.002(1)	−0.000(1)
N(2)	4e	0.7224(2)	0.6990(2)	0.7205(2)	0.013(1)	0.014(1)	0.013(1)	0.001(1)	0.007(1)	0.001(1)
C(1)	4e	0.6861(3)	0.5578(3)	0.8493(2)	0.016(2)	0.012(2)	0.012(2)	0.002(1)	0.004(1)	−0.006(1)
C(2)	4e	0.9281(3)	0.5107(3)	0.8857(2)	0.016(2)	0.031(2)	0.020(2)	0.004(2)	0.001(1)	0.003(2)
C(3)	4e	0.8357(3)	0.6479(3)	0.7717(2)	0.017(2)	0.013(2)	0.017(2)	0.000(1)	0.006(1)	−0.005(1)
C(4)	4e	0.7432(3)	0.7712(3)	0.6521(2)	0.022(2)	0.018(2)	0.024(2)	0.000(1)	0.015(1)	0.004(2)
C(5)	4e	0.5943(3)	0.6804(3)	0.7309(2)	0.014(2)	0.010(2)	0.015(2)	0.001(1)	0.004(1)	−0.004(1)
C(6)	4e	0.5724(3)	0.6097(3)	0.7927(2)	0.012(2)	0.010(2)	0.010(2)	0.002(1)	0.003(1)	−0.001(1)
C(7)	4e	0.4341(3)	0.5721(3)	0.8018(2)	0.013(2)	0.011(2)	0.013(2)	0.002(1)	0.005(1)	0.004(1)
C(8)	4e	0.3651(3)	0.6667(3)	0.8443(2)	0.011(1)	0.012(2)	0.014(2)	−0.000(1)	0.004(1)	0.000(1)
C(9)	4e	0.3442(3)	0.6417(3)	0.9188(2)	0.010(2)	0.013(2)	0.016(2)	0.002(1)	0.004(1)	0.001(1)
C(10)	4e	0.2872(3)	0.7316(3)	0.9686(2)	0.021(2)	0.020(2)	0.016(2)	0.002(1)	0.005(1)	−0.004(1)
C(11)	4e	0.2832(3)	0.8633(3)	0.9362(2)	0.019(2)	0.019(2)	0.024(2)	−0.001(1)	0.008(2)	−0.008(2)
C(12)	4e	0.2260(3)	0.8613(3)	0.8444(2)	0.020(2)	0.012(2)	0.027(2)	0.006(1)	0.011(2)	0.003(1)
C(13)	4e	0.3064(3)	0.7777(3)	0.8035(2)	0.008(2)	0.014(2)	0.021(2)	−0.005(1)	0.003(1)	−0.001(1)
C(14)	4e	0.3416(3)	0.5180(3)	0.7247(2)	0.011(2)	0.010(2)	0.015(2)	0.001(1)	0.004(1)	0.006(1)
C(15)	4e	0.2019(3)	0.5240(3)	0.7106(2)	0.016(2)	0.017(2)	0.011(2)	0.002(1)	0.007(1)	0.001(1)
C(16)	4e	0.1190(3)	0.4645(3)	0.6450(2)	0.009(2)	0.020(2)	0.020(2)	−0.002(1)	0.004(1)	0.004(2)
C(17)	4e	0.1754(3)	0.3975(3)	0.5925(2)	0.017(2)	0.015(2)	0.013(2)	−0.006(1)	0.001(1)	0.002(1)
C(18)	4e	0.3132(3)	0.3909(3)	0.6042(2)	0.019(2)	0.016(2)	0.013(2)	0.003(1)	0.007(1)	0.002(1)
C(19)	4e	0.3950(3)	0.4519(3)	0.6699(2)	0.009(2)	0.016(2)	0.019(2)	−0.000(1)	0.006(1)	0.001(1)

one. All geometric parameters of the title molecule are in the expected ranges.

Acknowledgements: The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at King Saud University for its funding this Research group NO (RG -044-1435-1436).

References

1. Al-Majid, A. M.; Barakat, A.; Al-Najjar, H. J.; Mabkhot, Y. N.; Ghabbour, H. A.; Fun, H.-K.: Tandem Aldol-Michael reactions in aqueous diethylamine medium: A greener and efficient approach to bis-pyrimidine derivatives. *Int. J. Mol. Sci.* **14** (2013) 23762–23773.
2. Bojarski, J. T.; Mokroc, J. L.; Barton, H. J., Paluchowska, M. H.: Recent progress in barbituric acid chemistry. *Adv. Heterocycl. Chem.* **38** (1985) 229–297.
3. Sans, S. R. G.; Chosaz, M. G.: Historical aspects and applications of barbituric acid derivatives. *Pharmazie* **43** (1988) 827–829.
4. Taylor, J. B.: *Modern Medical Chemistry*, Prentice Hall: New York, NY, USA, 1994.
5. Barakat, A.; Al-Najjar, H. J.; Al-Majid, A. M.; Soliman, S. M.; Mabkhot, Y. N.; Shaik, M. R.; Ghabbour, H. A.; Fun, H.-K.: Synthesis, NMR, FT-IR, X-ray structural characterization, DFT analysis and isomerism aspects of 5-(2,6-dichlorobenzylidene)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione. *Spectrochim. Acta* **147** (2015) 107–115.
6. Barakat, A.; Al-Majid, A. M.; Al-Najjar, H. J.; Choudhary, M. I.; Yousuf, S. S.: Crystal structure of 1,3-dimethyl-5-(2,4,6-trimethylbenzylidene)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione. *Z. Kristallogr. NCS* **229** (2014) 269–270.
7. Barakat, A.; Al Majid, A. M. A.; Al-Najjar, H. J.; Mabkhot, Y. N.; Javaid, S.; Yousuf, S.; Choudhary, M. I. Zwitterionic pyrimidinium adducts as antioxidants with therapeutic potential for nitric oxide scavenger. *Euro. J. Med. Chem.* **84** (2014) 146–154.
8. Barakat, A.; Soliman, S. M.; Al-Majid, A. M.; Lotfy, G.; Ghabbour, H. A.; Fun, H.-K.; Yousuf, S.; Choudhary, M. I.; Wadood, A.: Synthesis and structure investigation of novel pyrimidine-2,4,6-trione derivatives of highly potential biological activity as anti-diabetic agent. *J. Mol. Struct.* **1098** (2015) 365–376.
9. Barakat, A.; Al-Majid, A. M.; Soliman, S. M.; Lotfy, G.; Ghabbour, H. A.; Fun, H.-K.; Wadood, A.: New diethyl ammonium salt of thiobarbituric acid derivative: synthesis, molecular structure investigations and docking studies. *Molecules* **20** (2015) 20642–20658.
10. Barakat, A.; Islam, M. S.; Al-Majid, A. M.; Al-Othman, Z.; Soliman, S. M.; Ghabbour, H. A.; Fun, H.-K.: Synthesis of novel 5-monoalkylbarbiturates derivatives: New access to 1,2-oxazepines. *Tetrahedron Lett.* **56** (2015) 6984–6987.
11. Barakat, A.; Islam, M. S.; Al-Majid, A. M.; Ghabbour, H. A.; Fun, H.-K.; Javed, K.; Imad, R.; Yousuf, S.; Choudhary, M. I.; Wadood, A.: Synthesis, *in vitro* biological activities and *in silico* study on dihydropyrimidines derivatives. *Bioorg. Med. Chem.* **23** (2015) 6740–6748.
12. Bruker: APEX2, SAINT and SADABS. Bruker AXS Inc., Madison, Wisconsin, USA, 2009.
13. Sheldrick, G. M.: A short history of SHELX. *Acta Crystallogr. A* **64** (2008) 112–122.